PRAC warns of risk of hepatitis B re-activation with direct-acting antivirals for hepatitis C
Review of liver cancer risk not conclusive and further studies are needed
EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) has confirmed that patients treated with medicines known as direct-acting antivirals for hepatitis C may be at risk of hepatitis B re-activation. As a result of this review, the PRAC has recommended that, before starting treatment, all patients should be screened for hepatitis B virus; those patients co-infected with hepatitis B and C viruses must then be monitored and managed according to current clinical guidelines.
More information:
PRAC warns of risk of hepatitis B re-activation with direct-acting antivirals for hepatitis C
